Hold Rating for WW International Amid Uncertainty and Mixed Financial Outlook

In a report released yesterday, Nathan Feather from Morgan Stanley maintained a Hold rating on WW International (WW – Research Report), with a price target of $1.10.

Nathan Feather has given his Hold rating due to a combination of factors, primarily stemming from WW International’s recent financial performance and future outlook. The company’s fourth-quarter results for 2024 were better than anticipated, yet there remains a significant lack of clarity regarding its performance in 2025. This uncertainty is compounded by challenges related to compounded medication, which makes it difficult to predict future trends with confidence.
Nathan Feather also notes the strength in WW’s clinic segment, which has led to an increase in revenue estimates for 2025 and 2026. However, the lower gross margin of this segment means that the increase in gross profit is more modest. Additionally, while there is an expected scale in Clinical that could offset higher short-term SG&A expenses, the overall uncertainty and variability in financial projections have led to maintaining a base case range of $0.10-$2.10. This range reflects the potential volatility and justifies the Hold rating.